Previous / Next

[20110527. Issues on duodenal ulcer (9): selection of medication for maintenance treatment (continued)]

½ÊÀÌÁöÀå ±Ë¾ç ÇùÂøÀ¸·Î Ÿ º´¿ø¿¡¼­ ¼ö¼úÀ» ±ÇÀ¯¹ÞÀº ȯÀÚ¿´´Âµ¥ ±Ý½Ä°ú »ê¾ïÁ¦Ä¡·á·Î À½½ÄÀ» µå½Ç ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÌ ÀÖ¾ú°í Ä¡·á¸¦ ÇÏ¿´½À´Ï´Ù.

Àú´Â PPI¸¦ ÀÌ¿ëÇÑ longterm maintenance¸¦ ±ÇÇÏ¿´½À´Ï´Ù. À̹ø¿¡´Â ´ÙÇེ·´°Ô ºÎÁ¾ÀÌ ºüÁö¸é¼­ ½Ä»ç¸¦ ÇÏ½Ã°Ô µÇ¾ú½À´Ï´Ù. ÇÏÁö¸¸ ¶Ç ´Ù½Ã Àç¹ßÇÑ´Ù¸é °ÅÀÇ Æ²¸²¾øÀÌ ¼ö¼úÀ» ¹Þ¾Æ¾ß ÇÒ °Í °°´Ù°í »ý°¢ÇÏ¿´½À´Ï´Ù.


Gastric outlet obstruction due to duodenal ulcer stricture·Î ¿À½Å ºÐÀÔ´Ï´Ù.


[±Ë¾ç Àç¹ßÀ̳ª NSAIDs ±Ë¾çÀ¸·Î PPI Àå±â º¹¿ëÇϽô ºÐÀÌ PPI¸¦ ²÷¾úÀ» ¶§ÀÇ À§Ç輺]

¾Æ·¡ ȯÀÚ´Â ÀÚÀÇ·Î PPIÀ» ²÷´Â °ÍÀÌ ¾ó¸¶³ª À§ÇèÇÑÁö Àß º¸¿©ÁÝ´Ï´Ù. Attenuated FAP ¼ö¼ú ÈÄ ½ÊÀÌÁöÀå õ°øÀÌ ÀÖ¾î primary repair¸¦ Çϼ̴ø ºÐÀÔ´Ï´Ù (»ó¼¼ º´·ÂÀº ¾Ë ¼ö ¾øÀ½. Ÿº´¿ø ¼ö¼ú). ¸î ³â ÈÄ ½ÊÀÌÁöÀå±Ë¾ç ÃâÇ÷·Î ³»¿øÇÏ¿© ÀÔ¿øÄ¡·áÇÏ¿´°í esomeprazoleÀ» Åõ¿©ÇÏ¿´À¸¸ç Æò»ý µå½Ãµµ·Ï °­Á¶ÇÏ¿© ¼³¸íÇÏ¿´½À´Ï´Ù. ±×·±µ¥ ¸î °³¿ù ÈÄ CVA°¡ ¹ß»ýÇÏ¿© Àαٺ´¿ø¿¡ ÀÔ¿øÇÏ¿© Ä¡·á ÈÄ aspirin°ú silostazoleÀ» º¹¿ëÇϼ̴µ¥ esomeprazoleÀº ó¹æµÇÁö ¾Ê¾Ò°í, ȯÀÚµµ Áý¿¡ ³²¾ÆÀÖ´ø esomeprazoleÀ» µå½ÃÁö ¾Ê¾Ò½À´Ï´Ù. ±×¸®°í ¸çÄ¥ ÈÄ ½ÊÀÌÁöÀå±Ë¾ç ÃâÇ÷·Î ´Ù½Ã ÀÔ¿øÇϼ̽À´Ï´Ù. EsomeprazoleÀ» Åõ¿©ÇÏ¿´À¸¸ç "Æò»ý µå½Ãµµ·Ï" 10¹ø °­Á¶ÇÏ¿© ¼³¸íÇÏ¿´½À´Ï´Ù. °í·É ȯÀÚ¿¡°Ô ¿©·¯ ¹®Á¦°¡ ¹ß»ýÇÒ ¼ö Àִµ¥... ȯÀÚ°¡ esomeprazoleÀ» ²÷Áö ¾Ê°í Æò»ý µå½Ç ¼ö ÀÖÀ»Áö ÀÇ»ç·Î¼­ °ÆÁ¤ÀÌ ÅÂ»ê °°½À´Ï´Ù.

(2018. 71¼¼ ¿©¼º)

[Home]